Ethris GmbH

Ethris GmbH is a privately held clinical stage company focused on development of disruptive mRNA therapeutics for severe respiratory diseases, including uncontrolled asthma & COPD, and primary ciliary dyskinesia (PCD) through best-in-industry delivery, stability and nasal/nebulisation delivery technologies.

Ethris' novel, proprietary technology platform consisting of SNIM RNA , SNaP LNP and Stabilizer preventing LNP aggregation which affords multi-route, multi-cargo delivery options for intramuscular, inhaled or nasal administration and suitable for several genetic medicine payloads including mRNA and gene editing technologies such as CRISPR/Cas.

Development Pipeline:

1. ETH47: nasal delivery of mRNA for uncontrolled asthma & COPD , Phase 1 top-line data inc. safety, PK and PD, available, Phase IIa ongoing
2. Rare respiratory diseases including, primary ciliary dyskinesia (PCD)
3. Vaccines (i.m. and nasal delivery) including a spray-dried mucosal vaccine supported by CEPI

Proprietary platform capabilities overcome key obstacles of currently available mRNA and LNP technology:

1. Superior Stability: Proprietary stabilizer induces vibration resistance, and SNaP LNP offers stability at room temperature for 6 days. Scalable lyophilization and spray-drying removes ultra-cold chain requirements (15 months stability data at room temp)
2. Best-in-class nebulization: Proprietary stabilizer prevents LNP aggregation across relevant dose range leading to lower inhalation time and no risk of aggregate-related immunity
3. Potent delivery: SNaP LNP delivers mRNA into the respiratory tract with very high efficiency
4. Precise delivery: localised biodistribution at site of delivery (lung/nasal/i.m/s.c/implants etc.)
5. Lower immunogenicity: SNIM RNA modifications have 11x lower immunogenicity vs. non-modified mRNA which is comparable to N1M modification